Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView”
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
Search
Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
Human Health
Human Health
More Potential
Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
Vaccines
Vaccines
Horses
Horses
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
10 years of Making More Health
Leading Science in Oncology
As the oncology community learns more about the complexity of tumor biology, we are discovering new and exciting therapeutic opportunities.
Reggie the Red Blood Cell
Join Reggie, our curious red blood cell, on a journey exploring connections between the heart, kidneys and pancreas.
Science Stories
Science Stories
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk
Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk factors associated with type 2 diabetes
Our Health and Safety initiative - BE SAFE
Health and safety are of great importance to Boehringer Ingelheim.
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
Patient Centricity
Patient Centricity
Our Responsibility
Human Health Our Responsibility
Clinical Trial Demonstrates Positive Top-Line Results Reducing Risk Cardiovascular
Clinical Trial Demonstrates Positive Top-Line Results in Reducing the Risk for Cardiovascular Death or Hospitalisation due to Heart Failure
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
The ILD summit discussed the latest treatment guidelines for ILD which vastly impacts quality of life
Pets
Pets
Veterinary Public Health
Veterinary Public Health
Guardians for health
A global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guidelines.
Listen to the sounds disrupting farms worldwide
A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care